EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury

Elisha Purcell, Timothy Nguyen, Madeleine Smith, Tayla Penny, Madison C B Paton, Lindsay Zhou iD, Graham Jenkin, Suzanne L Miller, Courtney A McDonald, Atul Malhotra iD

Stem Cells Translational Medicine · 2023

DOI: 10.1093/stcltm/szad006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2023. Verfasst von Elisha Purcell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Fetal Blood, Brain Injuries. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Australia and Cerebral Palsy Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics.

Objectives

To systematically review the effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand the contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage, and number of doses.

Methods

A systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi2 test where possible.

Results

Differential benefits of UCBCs were seen across a number of subgroup analyses including intraventricular hemorrhage (IVH) vs. hypoxia ischemia (HI) model (apoptosis white matter (WM): chi2 = 4.07; P = .04, neuroinflammation-TNF-α: chi2 = 5.99; P = .01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi2 = 5.01; P = .03, neuroinflammation-TNF-α: chi2 = 3.93; P = .05, apoptosis grey matter (GM), astrogliosis WM), and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi2 = 7.51; P = .02, astrogliosis WM: chi2 = 12.44; P = .002). We identified a serious risk of bias and overall low certainty of evidence.

Conclusions

Preclinical evidence suggests UCBCs to show greater efficacy in the injury model of IVH compared to HI, the use of UCB-MSCs compared to UCB-MNCs and the use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence and address knowledge gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal BloodBrain InjuriesAnimalsFemalePregnancyHumansAnimals, NewbornNeuroinflammatory DiseasesTumor Necrosis Factor-alphaGliosisIschemiaCerebral Hemorrhage

Stichwörter der Autor:innen

brain injuriescord blood stem cell transplantationfetal bloodperinatal caresystematic review

Substanzen

Tumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Paediatrics, Monash University, Melbourne, Australia.
  • The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia.
  • Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.
  • Cerebral Palsy Alliance Research Institute, & Speciality of Child and Adolescent Health, The University of Sydney, Sydney, Australia.
  • Monash Newborn, Monash Children's Hospital, Melbourne, Australia.

ORCID-Profile: Lindsay Zhou, Atul Malhotra

Förderung

  • National Health and Medical Research Council
  • Australia and Cerebral Palsy Alliance

Zitieren

APA

Purcell, E., Nguyen, T., Smith, M., Penny, T., Paton, M. C. B., Zhou, L., Jenkin, G., Miller, S. L., McDonald, C. A., & Malhotra, A. (2023). Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szad006

Vancouver

Purcell E, Nguyen T, Smith M, Penny T, Paton MCB, Zhou L, et al. Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury. Stem Cells Translational Medicine. 2023. doi:10.1093/stcltm/szad006

BibTeX
@article{Purcell2023,
  author = {Purcell, Elisha and Nguyen, Timothy and Smith, Madeleine and Penny, Tayla and Paton, Madison C B and Zhou, Lindsay and Jenkin, Graham and Miller, Suzanne L and McDonald, Courtney A and Malhotra, Atul},
  title = {Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury},
  journal = {Stem Cells Translational Medicine},
  year = {2023},
  doi = {10.1093/stcltm/szad006}
}
Kostenlos starten →